MAGEA3 and melanoma: Nishiyama et al. showed that a combination of melanoma antigens-3 (MAGE-3) antigen peptide (IMPKAGLLI) and HLA-A24-sensitized DCs possessed significantly elevated ability to induce a MAGE-3+ cell-specific CTLs response compared with MAGE-3-expressing UBC cells or non-pulsed DCs in vitro [111].